Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting ...Middle East

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and toripalimab in patients with advanced solid tumors TORCH-2 is the world's first clinical study evaluating the combination of a dual mTORC1/2 inhibitor and an anti-PD-1 monoclonal antibody...

Hence then, the article about antengene to present clinical results of atg 008 onatasertib at the 2022 american society of clinical oncology annual meeting was published today ( Wednesday 01/06/2022 - 03:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting )

Also on site :

• ‘The Final Girl Support Group’ Heads To Paramount As Feature To Be Directed & Adapted By Christopher Landon; Aperture & Muschiettis’ Double Dream Producing
• Marc Blumberg Arrested for Lewd Acts on a Child While Working at Moorpark Equestrian Facility; Additional Survivors Expected
• Inside China’s two-speed economy: Why goods consumption is slumping even as exports and services boom